Compare Neurocrine Biosciences Inc (NBIX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs First Trust Cloud Computing ETF — how do they compare? Neurocrine Biosciences Inc trades at $155.5 (market cap $15.77B), while First Trust Cloud Computing ETF trades at $158.14. The key difference: First Trust Cloud Computing ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| NBIX | SKYY | |
|---|---|---|
Market Cap | $15.77B | — |
Sector | Health | — |
52-Week High | $185.50 | $168.91 |
52-Week Low | $123.10 | $104.16 |
Enterprise Value | $15.78B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
SKYY, the First Trust Cloud Computing ETF, trades at $159.62, down 1.2% today, with a neutral technical signal. It offers diversified exposure to cloud infrastructure and software, benefiting from AI adoption and digital transformation trends. Recent news highlights strong infrastructure spending and AI demand driving cloud computing growth, positioning SKYY for potential long-term gains.
The outlook for SKYY is positive due to secular trends in cloud migration and AI, though risks include market volatility and sector concentration. Analyst sentiment is cautiously optimistic, with institutional interest supporting the ETF's role in technology sector allocations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
